Download the Protocol

VIP (Vasoactive Intestinal Peptide)

VIP is a natural peptide that helps relax blood vessels, calm inflammation, and protect tissues in the body. It plays roles in breathing, digestion, and immune balance, and is being studied for conditions like asthma, lung inflammation, and chronic fatigue syndromes.

Description

• Vasoactive Intestinal Peptide (VIP) is a 28–amino-acid neuropeptide found throughout the nervous system.
• Functions as a neurotransmitter, vasodilator, and immune modulator.
• Investigated for therapeutic use in inflammatory, pulmonary, and neuroendocrine disorders.

How It Works

• Binds to VPAC1 and VPAC2 receptors, activating cAMP signaling inside cells.
• Relaxes smooth muscle, improving airflow and blood flow.
• Reduces inflammatory cytokine production and supports balanced immune signaling.

Documented Effects

• Improves airway dilation and breathing function in respiratory studies.
• Reduces inflammation and oxidative stress markers in preclinical trials.
• Supports vascular health, gut barrier protection, and neuroimmune regulation.

Theoretical Effects

• Potential applications in chronic inflammatory response syndrome (CIRS), asthma, and pulmonary hypertension.
• May promote relaxation, improved sleep, and nervous system recovery.
• Limited bioavailability with injections; nasal formulations under research for better absorption.

Pharmacokinetics

• Half-life: approximately 2 minutes intravenously; extended by analog or nasal delivery.
• Peak effect: rapid onset within minutes, short duration unless sustained-release form used.
• Duration: physiological effects last 30–60 minutes; downstream anti-inflammatory benefits may persist longer.

Reconstitution

• Use only bacteriostatic water to reconstitute the lyophilized powder.
• Example vial: 10 mg VIP
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve; do not shake or heat.
• Refrigerate reconstituted solution (2–8 °C). Use within ~14 days for best stability.

Injectable Dosage Overview (Research Use)

Typical Starting Dose

• Research range: 25–100 mcg subcutaneous (SC) per dose.
• Conservative start: 25 mcg once daily to assess tolerance and hemodynamic response.

Common Research Range

• 100–500 mcg SC once or twice daily depending on the experimental model.
• Intranasal protocols: 50–100 mcg per spray, 1–2 times daily.

Maximum Research Range

• Typical ceiling: ~1 mg per day (split into smaller doses).
• Higher dosing may cause transient hypotension or flushing.

Standard Cycle Length

• Short-term research: 2–4 weeks of daily administration.
• Cycles often alternated with rest periods to evaluate recovery and immune response.

Clinical Notes

• Administered intranasally or subcutaneously; intranasal use is preferred for neurological, respiratory, or autonomic benefits.
• Known for strong vasodilatory and bronchodilatory effects; may improve breathing comfort in sensitive individuals.
• Can support autonomic balance, reduce inflammatory signaling, and improve cognitive clarity in some users.
• May cause transient lightheadedness, facial flushing, or mild drop in blood pressure, especially at higher doses.
• Avoid use before activities requiring rapid position changes due to potential orthostatic sensitivity.
• Stable for about 14 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• May cause mild flushing, lightheadedness, or short-term drop in blood pressure.
• Avoid combining with other strong vasodilators during testing.
• Use only under controlled, sterile, and research-approved conditions.
• Not approved for clinical or therapeutic human use outside of regulated studies.